We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Positive Results Announced From Pivotal Study of Bendamustine in Non-Hodgkin's Lymphoma.
- Abstract
The article announces positive results from a phase III clinical trial of bendamustine in patients with indolent non-Hodgkin's lymphoma (NHL) whose cancer is no longer responsive to treatment with rituximab by Cephalon Inc. in the U.S. The said study evaluated the efficacy and safety of single-agent bendamustine in 100 patients with relapsed, rituximab-refractory NHL. The protocol for the NHL pivotal trial received special protocol assessment (SPA) approval from the Food & Drug Administration..
- Subjects
UNITED States; CLINICAL trials; HODGKIN'S disease; RITUXIMAB; CANCER treatment; DRUG approval; CEPHALON Inc.; UNITED States. Food &; Drug Administration
- Publication
Oncology (08909091), 2007, Vol 21, Issue 12, p1496
- ISSN
0890-9091
- Publication type
Article